{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:08:56Z","timestamp":1790690936563,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological and Toxicological Methods"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.vascn.2026.108576","type":"journal-article","created":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T22:11:38Z","timestamp":1790547098000},"page":"108576","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Integration of safety pharmacology endpoints into toxicology studies - A survey of GLP institutions in China"],"prefix":"10.1016","volume":"142","author":[{"given":"Bin","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailing","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqin","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuewu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Valentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Pierson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael K.","family":"Pugsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jufeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vascn.2026.108576_bb0005","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.vascn.2016.06.001","article-title":"Safety pharmacology investigations on the nervous system: An industry survey","volume":"81","author":"Authier","year":"2016","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2026.108576_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2025.108378","article-title":"Toxicology and safety pharmacology investigations on the nervous system: 2024 industry survey","volume":"135","author":"Authier","year":"2025","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"1","key":"10.1016\/j.vascn.2026.108576_bb0015","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.vascn.2013.05.002","article-title":"Safety pharmacology investigations in toxicology studies: An industry survey","volume":"68","author":"Authier","year":"2013","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2026.108576_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2021.107067","article-title":"The in vivo QTc core assay: An evaluation of QTc variability, detection sensitivity and implications for the improvement of conscious dog and non-human primate telemetry studies","volume":"109","author":"Baublits","year":"2021","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2026.108576_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2025.107757","article-title":"Telemetry in toxicology studies\u2013a comparison of data across species, technologies and time","volume":"134","author":"Best","year":"2025","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"4","key":"10.1016\/j.vascn.2026.108576_bb0030","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1517\/14740338.2013.798300","article-title":"2012 annual meeting of the safety pharmacology society: Spotlight on targeted oncology medicines","volume":"12","author":"Cavero","year":"2013","journal-title":"Expert Opinion on Drug Safety"},{"key":"10.1016\/j.vascn.2026.108576_bb0035","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2026.1813708","article-title":"25 years of applying the 3Rs principles in safety pharmacology: Success stories and future perspectives","volume":"17","author":"Derakhchan","year":"2026","journal-title":"Frontiers in Physiology"},{"issue":"L324","key":"10.1016\/j.vascn.2026.108576_bb0040","first-page":"121","article-title":"Regulation (EC) no 1394\/2007 of the European Parliament and of the council on advanced therapy medicinal products and amending. Directive 2001\/83\/EC and regulation (EC) no 726\/2004","volume":"50","author":"European Commission","year":"2007","journal-title":"Official Journal of the European Union"},{"issue":"2","key":"10.1016\/j.vascn.2026.108576_bb0045","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.taap.2013.04.039","article-title":"Safety pharmacology\u2014Current and emerging concepts","volume":"273","author":"Hamdam","year":"2013","journal-title":"Toxicology and Applied Pharmacology"},{"key":"10.1016\/j.vascn.2026.108576_bb0050","author":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use"},{"key":"10.1016\/j.vascn.2026.108576_bb0060","author":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use"},{"key":"10.1016\/j.vascn.2026.108576_bb0065","author":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use"},{"key":"10.1016\/j.vascn.2026.108576_bb0070","author":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use"},{"key":"10.1016\/j.vascn.2026.108576_bb0075","doi-asserted-by":"crossref","first-page":"108575","DOI":"10.1016\/j.vascn.2026.108575","article-title":"Weight of evidence in safety pharmacology guidance: A case for explicit probabilistic reasoning in the revision of ICH S7A","volume":"142","author":"Leishman","year":"2026","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"2","key":"10.1016\/j.vascn.2026.108576_bb0080","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1046\/j.1472-8206.2002.00084.x","article-title":"Integration of safety pharmacology endpoints into toxicology studies","volume":"16","author":"Luft","year":"2002","journal-title":"Fundamental & Clinical Pharmacology"},{"key":"10.1016\/j.vascn.2026.108576_bb0085","article-title":"Best practices for use of adversity and NOAEL in safety pharmacology: Toward cross-disciplinary harmonization","author":"Martel","year":"2026","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2026.108576_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2020.106917","article-title":"Is there a role for the no observed adverse effect level in safety pharmacology?","volume":"105","author":"Mow","year":"2020","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2026.108576_bb0095","author":"National Medical Products Administration (NMPA)"},{"key":"10.1016\/j.vascn.2026.108576_bb0100","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/978-3-662-46943-9_14","article-title":"Inclusion of safety pharmacology endpoints in repeat-dose toxicity studies","author":"Redfern","year":"2015","journal-title":"Principles of Safety Pharmacology"},{"issue":"4","key":"10.1016\/j.vascn.2026.108576_bb0105","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1039\/c3tx20093k","article-title":"Functional assessments in repeat-dose toxicity studies: The art of the possible","volume":"2","author":"Redfern","year":"2013","journal-title":"Toxicology Research"},{"issue":"3","key":"10.1016\/j.vascn.2026.108576_bb0110","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1046\/j.1472-8206.2002.00098.x","article-title":"Safety pharmacology\u2013a progressive approach","volume":"16","author":"Redfern","year":"2002","journal-title":"Fundamental & Clinical Pharmacology"},{"key":"10.1016\/j.vascn.2026.108576_bb0115","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.vascn.2016.12.004","article-title":"Detecting drug-induced changes in ECG parameters using jacketed telemetry: Effect of different data reduction techniques","volume":"85","author":"Skinner","year":"2017","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2026.108576_bb0120","doi-asserted-by":"crossref","first-page":"106096","DOI":"10.1016\/j.yrtph.2026.106096","article-title":"Revisiting ICH S7A after 25 years: Outcomes of a multi-stakeholder workshop and strategic pillars for modernizing safety pharmacology","volume":"169","author":"Valentin","year":"2026","journal-title":"Regulatory Toxicology and Pharmacology"},{"key":"10.1016\/j.vascn.2026.108576_bb0125","article-title":"Current practices on the measurement of electrocardiogram and hemodynamic parameters in non\u2013rodent species in regulatory safety assessment studies","volume":"135","author":"Valentin","year":"2025","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2026.108576_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2025.107763","article-title":"Results from an EFPIA, JPMA, PhRMA industry survey on reopening and revamping the ICH S7A guidance on safety and secondary pharmacology","volume":"135","author":"Valentin","year":"2025","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2026.108576_bb0135","doi-asserted-by":"crossref","first-page":"100599","DOI":"10.1016\/j.cotox.2026.100599","article-title":"Recommendations on the measurement of cardiovascular parameters in non-rodent species for regulatory safety assessment of pharmaceuticals","volume":"47","author":"Valentin","year":"2026","journal-title":"Current Opinion in Toxicology"},{"key":"10.1016\/j.vascn.2026.108576_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2025.105795","article-title":"Points to consider for revising the ICH S7A guideline on safety and secondary pharmacology","volume":"159","author":"Valentin","year":"2025","journal-title":"Regulatory Toxicology and Pharmacology"},{"issue":"1","key":"10.1016\/j.vascn.2026.108576_bb0145","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1517\/14740338.2013.745851","article-title":"Non-clinical strategy considerations for safety pharmacology: Evaluation of biopharmaceuticals","volume":"12","author":"Vargas","year":"2013","journal-title":"Expert Opinion on Drug Safety"},{"issue":"24","key":"10.1016\/j.vascn.2026.108576_bb0150","first-page":"3049","article-title":"Consideration of non-clinical safety pharmacology evaluation of biopharmaceutics","volume":"38","author":"Yin","year":"2022","journal-title":"Chinese Journal of Clinical Pharmacology"}],"container-title":["Journal of Pharmacological and Toxicological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871926001693?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871926001693?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:52:05Z","timestamp":1790689925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056871926001693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":29,"alternative-id":["S1056871926001693"],"URL":"https:\/\/doi.org\/10.1016\/j.vascn.2026.108576","relation":{},"ISSN":["1056-8719"],"issn-type":[{"value":"1056-8719","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integration of safety pharmacology endpoints into toxicology studies - A survey of GLP institutions in China","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological and Toxicological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vascn.2026.108576","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108576"}}